SHARE:   Share to Facebook Share to Twitter Share to Linked In Share via Email  

Back To Search Results

C56 - Case Studies: Neurologic Consultations in Cancer Patients II

Event Time: Sunday April 23, 2017 3:30 pm to 5:30 pm
Topic(s): Neuro-oncology
Director(s): Patrick Wen MD, FAAN
Description: Neurologists are often called upon to weigh in on management issues related to patients with brain tumors or systemic cancer. They must recognize syndromes that predate cancer diagnosis, complications of therapy, and sequelae. The program will be divided into three sessions using cases to illustrate 1) the current management and new WHO classification of gliomas, 2) the diagnosis and management of metastatic complications of cancer, and 3) recent developments in the diagnosis and management of paraneoplastic neurologic syndromes. These presentations will be followed by a fourth session involving a tumor board format to discuss cases of interest. This program complements C38: Case Studies: Neurologic Consultations in Cancer Patients I, but covers independent topics.
Completion Message: Participants should be able to understand the current diagnosis, classification, and management of gliomas; the diagnosis and management of the common metastatic complications of cancer; and the diagnosis and management of paraneoplastic syndromes of the nervous system.
CME Credits: 2
Core Competencies: Medical Knowledge, Patient Care

Program Speakers - Tentative

Start/End Time Title Faculty
3:30 PM - 4:00 PM Update on WHO Classification and Treatment of Gliomas Patrick Wen MD, FAAN 
4:00 PM - 4:30 PM Diagnosis and Management of Metastatic Complications of Cancer David Schiff MD, FAAN 
4:30 PM - 5:00 PM Diagnosis and Management of Paraneoplastic Syndromes Josep Dalmau MD, PhD, FAAN 
5:00 PM - 5:30 PM Tumor Board Case Studies Amy Pruitt MD 

Disclosures

Speaker Disclosure
Josep O. Dalmau, MD, PhD, FAAN Dr. Dalmau has received personal compensation in an editorial capacity for Editor: Neurology, Neuroimmunology, Neuroinflammation; and UpToDate. Dr. Dalmau has received royalty, license fees, or contractual rights payments from Euroimmune. Dr. Dalmau has received research support from Euroimmun.

Amy A. Pruitt, MD Dr. Pruitt has nothing to disclose.

David Schiff, MD, FAAN Dr. Schiff has received personal compensation for activities with Genentech, Oxigene, Vascular Biogenics, and Orbus Therapeutics as an advisory board member and a DSMC.

Patrick Y. Wen, MD, FAAN Dr. Wen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck, Abbvie, AstraZeneca, Corice Bioscience, Roche, GW pharmaceuticals, Kadmon, Vascular Biogenics, Ziopharm. Dr. Wen has received personal compensation in an editorial capacity for Neuro-Oncology, UpToDate, Elsevier.

Register Now

Related Courses

Sunday April 22, 2018

9:15 AM-12:00 PM
PL2 Presidential Plenary Session

Wednesday April 25, 2018

1:00 PM-3:00 PM
C148 Neurologic Consultations in Cancer Patients I Amy Pruitt MD
3:30 PM-5:30 PM
C163 Neurologic Consultations in Cancer Patients II Patrick Wen MD, FAAN

Thursday April 26, 2018

7:00 AM-9:00 AM
C177 Neuro-oncology in 2018: Navigating Current Trends Maciej Mrugala MD
1:00 PM-3:00 PM
C189 Neuro-oncologic Predicaments in the Hospital Setting Na Tosha Gatson MD, PhD
3:30 PM-5:30 PM
N6 Neuroscience in the Clinic: Neurologic Complications of Cancer Immunotherapy: A New Frontier in Neuro-Inflammation Antonio Omuro MD,
Andreas Hottinger MD

MEMBER LOG IN

Forgot Password?